APA (7th ed.) Citation

Ho, A., Bowles, D., Even, C., Hao, D., Kang, H., Metcalf, R., . . . Ferrarotto, R. (2021). 904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort. Annals of oncology, 32, S803-S804. https://doi.org/10.1016/j.annonc.2021.08.1314

Chicago Style (17th ed.) Citation

Ho, A.L, et al. "904P ACCURACY: A Phase II Trial of AL101, a Selective Gamma Secretase Inhibitor, in Subjects with Recurrent/metastatic (R/M) Adenoid Cystic Carcinoma (ACC) Harboring Notch Activating Mutations (Notchmut): Results of 6-mg Cohort." Annals of Oncology 32 (2021): S803-S804. https://doi.org/10.1016/j.annonc.2021.08.1314.

MLA (9th ed.) Citation

Ho, A.L, et al. "904P ACCURACY: A Phase II Trial of AL101, a Selective Gamma Secretase Inhibitor, in Subjects with Recurrent/metastatic (R/M) Adenoid Cystic Carcinoma (ACC) Harboring Notch Activating Mutations (Notchmut): Results of 6-mg Cohort." Annals of Oncology, vol. 32, 2021, pp. S803-S804, https://doi.org/10.1016/j.annonc.2021.08.1314.